COMMUNIQUÉS West-GlobeNewswire

Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102)

29/11/2017 - 14:00

AUSTIN, Texas, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE ), a biotechnology company committed to the discovery and development of engineered human enzyme therapeutics for patients with [...]

Cancer Genetics and Indian Cooperative Oncology Network (ICON) Collaborate to Reduce Alarmingly Increasing Cancer Mortality Rates

29/11/2017 - 14:00

Goal to bring CGI’s global expertise in clinical diagnostic assay development and as a drug development partner to optimize clinical outcomes for cancer patients; Aim to develop educational and collaborative clinical [...]

Protalix BioTherapeutics Completes Enrollment in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis

29/11/2017 - 13:55

CARMIEL, Israel, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE: PLX ), announced today the completion of enrollment in the Company’s phase II clinical trial evaluating OPRX- [...]

A Personal Letter to the Shareholders from Michael T. Redman, CEO of Oncolix, Inc.

29/11/2017 - 13:30

HOUSTON, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Oncolix, Inc., (OTC PINK:ONCX) a company focused on developing new cancer therapeutics, announces a letter from the CEO. My fellow shareholders, First, I would like to thank [...]

U.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals’ IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma

29/11/2017 - 13:30

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA ), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients [...]

Actinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology Platform

29/11/2017 - 13:30

- Poster presentation to detail results from ongoing Phase 2 trial for Actimab-A, Actinium’s CD33 targeting ARC or Antibody Radio-Conjugate, designed to explore Actimab-A’s efficacy in patients newly diagnosed with [...]

Peer-Reviewed Article Published on Pluristem’s PLX-PAD Cells’ Mechanism of Action to Restore Blood Flow in Ischemic Tissue

29/11/2017 - 13:00

HAIFA, Israel, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (NASDAQ: PSTI ) (TASE: PSTI ), a leading developer of placenta-based cell therapy products, announced the publication of a peer-reviewed [...]

Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma

29/11/2017 - 13:00

ATLANTA, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ: AVIR ), a company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic [...]

ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa

29/11/2017 - 13:00

Key Updates ProQR’s drug candidate, QR-313 for dystrophic epidermolysis bullosa (DEB) receives orphan drug designation in the EU from the EMA. QR-313 also received U.S. ODD from the FDA in September 2017. QR-313 [...]

Emerald Health Therapeutics, Inc. Acquires Shares of Vanc Pharmaceuticals Inc.

29/11/2017 - 13:00

VICTORIA, British Columbia, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSX-V: EMH ) (OTCQX:EMHTF) ("Emerald" or the “Company”) announces that it acquired today 1,666,6667 units (the “Units”) of [...]

Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company

29/11/2017 - 13:00

- Acquisition positions Melinta as durable and focused pure-play antibiotics company with four marketed products: Baxdela ® , Vabomere ® , Orbactiv ® , and Minocin IV ® - - Peak sales potential of the portfolio post- [...]

ChromaDex to Present at the 10th Annual LD Micro Main Event

29/11/2017 - 12:30

IRVINE, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: CDXC ), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today that its Chief Executive [...]

United Health Products Announces Medical Device Approval for HemoStyp® in South African Market

29/11/2017 - 12:00

HENDERSON, Nev., Nov. 29, 2017 (GLOBE NEWSWIRE) -- United Health Products, Inc. (UHP) (OTC:UEEC), a manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today [...]

Zealand Pharma to attend three U.S. healthcare conferences in December

29/11/2017 - 10:38

Press release - No. 12 / 2017 Zealand Pharma to attend three U.S. healthcare conferences in December Copenhagen, November 29, 2017 - Britt Meelby Jensen, President and Chief Executive Officer (CEO) and Mats Blom, [...]

Trading by management and of close relations to management

29/11/2017 - 10:33

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes reports the [...]

Management change at ALK

29/11/2017 - 08:26

Copenhagen, 2017-11-29 08:26 CET (GLOBE NEWSWIRE) -- ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) today announced that Helle Skov, Executive Vice President (EVP) of Product Supply and a member of ALK's Board of [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

29/11/2017 - 07:01

REGULATED INFORMATION GHENT, Belgium, 29 November 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

MedMira Reports 2017 Fourth Quarter and Year End Financial Results

29/11/2017 - 00:45

HALIFAX, Nova Scotia, Nov. 28, 2017 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter and year ended July 31, 2017. MedMira’s Chief Financial Officer, Markus [...]

Cesca Therapeutics Inc. Announces Proposed Public Offering of Common Stock

28/11/2017 - 23:20

RANCHO CORDOVA, Calif., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ: KOOL ), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today [...]